Literature DB >> 3148668

Pharmacokinetics of recombinant murine interferon-gamma in mice.

I Rutenfranz1, H Kirchner.   

Abstract

Administration of interferon-gamma (IFN-gamma) provides a new approach to the treatment of tumors and viral and microbial infections. The aim of this study was to evaluate the pharmacokinetics of recombinant murine IFN-gamma (rMuIFN-gamma) in the mouse system as a model for future investigations of the therapeutical effect of IFN-gamma. After a bolus injection of 2 x 10(4) LU/mouse by the intravenous (i.v.) route, a biphasical elimination pattern of the antiviral activity from the serum was detected in female and male C57BL/6 and CBA/2 mice with a beta half-life time of 19-32 min. After intramuscular (i.m.) and subcutaneous (s.c.) injection of rIFN-gamma, antiviral activity in serum could be detected from 30 to 270 min after the bolus application. There was a plateau in the activity from 65 to 135 min after s.c. and from 84 to 143 min after i.m. injection. Both kinetics fit with a pharmacokinetic model of biphasical elimination with an entrance compartment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3148668     DOI: 10.1089/jir.1988.8.573

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  6 in total

1.  Gamma interferon functions in resistance to Cryptosporidium parvum infection in severe combined immunodeficient mice.

Authors:  W Chen; J A Harp; A G Harmsen; E A Havell
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

2.  Liposomes containing interferon-gamma as adjuvant in tumor cell vaccines.

Authors:  M L van Slooten; G Storm; A Zoephel; Z Küpcü; O Boerman; D J Crommelin; E Wagner; R Kircheis
Journal:  Pharm Res       Date:  2000-01       Impact factor: 4.200

3.  Cytokines are systemic effectors of lymphatic function in acute inflammation.

Authors:  Melissa B Aldrich; Eva M Sevick-Muraca
Journal:  Cytokine       Date:  2013-06-10       Impact factor: 3.861

4.  Systemic administration of interferon-gamma-expressing plasmid reduces late allergic bronchitis in a mouse model of asthma.

Authors:  T Hayashi; K Maeda; K Hasegawa; S Nakai; T Hamachi; H Iwata
Journal:  Int J Exp Pathol       Date:  2002-04       Impact factor: 1.925

5.  Systemic administration of olygodeoxynucleotides with CpG motifs at priming phase reduces local Th2 response and late allergic rhinitis in BALB/c mice.

Authors:  Toshiharu Hayashi; Keiko Hasegawa; Yuji Sasaki
Journal:  Inflammation       Date:  2007-09-12       Impact factor: 4.092

6.  Hemophagocytosis causes a consumptive anemia of inflammation.

Authors:  Erin E Zoller; Jennifer E Lykens; Catherine E Terrell; Julio Aliberti; Alexandra H Filipovich; Peter M Henson; Michael B Jordan
Journal:  J Exp Med       Date:  2011-05-30       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.